Therapy News and Research

RSS

Dr. Afar opens new dentistry office in North Hollywood, offers special promotion for new patients

Dr. Bijan Afar, a Dentist in Los Angeles who has been practicing for many years, is now opening a new office in the North Hollywood area and has a special promotional offer for all new patients. As a Dentist in North Hollywood, he is offering a dental examination complete with X-rays for the very reasonable price of only $49.00. This is an excellent opportunity for new patients to get acquainted with Dr. Afar and his staff of very talented professionals.

7 Aug 2010

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, cardiovascular and orthopedic areas, announced today its results for the second quarter of fiscal 2010.

7 Aug 2010

SIRIUS XM Radio to broadcast call-in show for autism spectrum disorders

SIRIUS XM Radio today announced that in partnership with Autism Speaks it will broadcast Doctor Radio Reports: Understanding Autism - Looking for Answers, a live, two-hour call-in show hosted by veteran journalist Perri Peltz on which a panel of world-class doctors, experts, scientists and parents of affected children will explore the latest research and treatment options for autism and disorders on the autism spectrum and take calls from listeners across the country.

7 Aug 2010

Asynchronous telepsychiatry provides primary-care physicians greater access to psychiatric consultation

A new study by researchers at the UC Davis School of Medicine has found that psychiatrists can accurately assess a patient's mental health by viewing videotaped interviews that are sent to them for consultation and treatment recommendations.

7 Aug 2010

Response Genetics total revenue for second-quarter 2010 increases 197% to $5.6 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and six months ended June 30, 2010.

7 Aug 2010

Scientists develop hand prosthesis that eases phantom pain

The pain of losing a body part is twofold, as the patients not only suffer from wound pain. Often they are also affected by so called phantom pain. Unlike bodily wounds which will eventually heal, phantom pain often lasts for years and sometimes a lifetime. "Phantom pain is very difficult to treat", says Professor Dr Thomas Weiss from the Friedrich-Schiller-University Jena.

7 Aug 2010

TrueBeam technology reduces cancer radiation treatment time

The Department of Radiation Oncology at the University of Alabama at Birmingham Comprehensive Cancer Center is among the world's first to begin using radiation technology that dramatically reduces treatment times.UAB's Hazelrig-Salter Radiation Oncology Center is the third U.S. site to acquire TrueBeam technology. TrueBeam, by Varian Medical Systems Inc., can complete a standard 40-minute radiation therapy in less than a minute for select patients. The precision of the instrument, measured in increments of less than a millimeter, comes from real-time patient imaging, positioning, beam shaping and many other data points synchronized continually as treatment progresses.

7 Aug 2010

UCSF researchers discover new technology purifying special types of stem cells

UCSF researchers are reporting the first success in very rapidly purifying one type of embryonic stem cell from a mix of many different types of embryonic stem cells in the culture dish. The technique, which avoids the need to genetically alter the cells to distinguish them, is a key advance, the researchers say, for obtaining the appropriate cells for repairing specific damaged tissues.

7 Aug 2010

Drugs that reduce activity of ABDH6 enzyme can prevent brain damage: Study

A newly discovered molecular mechanism helps control the amount and effectiveness of a substance that mimics an active ingredient in marijuana, but that is produced by the body's own nerve cells.

7 Aug 2010

FDA declines to grant Levulan PDT Orphan Designation: DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. reported today that on the afternoon of August 5, 2010 the U.S. Food and Drug Administration notified DUSA that it has not granted Orphan Drug Designation for the use of Levulan (aminolevulinic acid HCl) Photodynamic Therapy for the prevention of cutaneous squamous cell carcinomas in patients who have a proven history of multiple localized cutaneous SCCs over a 12 month period.

7 Aug 2010

Surgery offers high survival rate for prostate cancer patients: Study

Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies, according to a new study led by researchers at UCSF.The differences among therapies were more prominent at higher levels of cancer risk, and suggest, the researchers say, that in many cases surgery should play a greater role in treatment strategies for patients with prostate cancer that is likely to recur or spread.

7 Aug 2010

OncoGenex reports net income in second-quarter 2010 against loss last year

OncoGenex Pharmaceuticals, Inc. today reported unaudited financial results for the three and six months ended June 30, 2010 and reviewed the Company's highlights for the second quarter of 2010.

7 Aug 2010

BCF publishes two new patient publications

The Bone and Cancer Foundation is announcing the publishing of two new patient publications on Pain Management and Physical Therapy and other Rehabilitation Therapies. Other publication topics include: Breast Cancer, Prostate Cancer, Lung Cancer, Osteonecrosis of the Jaw, Vitamin D, Surgery, Myeloma and Osteosarcoma.

7 Aug 2010

S-ICD subcutaneous implantable defibrillator restores normal heartbeat in high risk cardiac arrest

Scottsdale Healthcare is the only Arizona hospital system testing a new under-the-skin device that uses an electrical shock to interrupt possibly fatal heart rhythms, restoring a normal heartbeat for patients at high risk of sudden cardiac arrest.The first Arizona patient received the device Thursday at Scottsdale Healthcare Shea Medical Center. Scottsdale Healthcare is the only Phoenix area hospital and one of only 35 in the world participating in the study.

7 Aug 2010

AVANIR Pharmaceuticals reports net loss of $5.7M for third-quarter fiscal 2010

AVANIR Pharmaceuticals, Inc. today reported unaudited financial results for the three and nine months ended June 30, 2010.

7 Aug 2010

Recent releases in Global Health

According to a Lancet Comment, "alcohol remains conspicuously absent from the larger field of research and programming in HIV and substance use. ... Patterns of hazardous alcohol consumption prevail in countries with the most severe HIV epidemics, notably eastern and southern Africa." In addition, "hazardous drinking patterns also dominate in the concentrated epidemics of eastern Europe and Asia, where alcohol use by injecting drug users and other marginalised groups might be an additional barrier to effective efforts to prevent HIV infection."

7 Aug 2010

JumpStart Ventures announces investment commitment of $250,000 in ChanRx

JumpStart Ventures, which invests in and partners with innovative, early-stage companies in Northeast Ohio, announced an investment commitment of $250,000 in drug development company ChanRx. The two-year-old company is developing a pharmaceutical compound to treat atrial fibrillation, a heart condition that affects two million Americans, with 200,000 new cases being diagnosed each year.

6 Aug 2010

ViroPharma announces data on safety, efficacy of Cinryze to treat acute angioedema attacks

ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.

6 Aug 2010

Select Medical teams up with Baylor, joint venture to provide quality health care

Baylor Health Care System and Select Medical Corporation announced today a proposed partnership between Baylor Institute for Rehabilitation and a wholly-owned subsidiary of Select that is designed to create a regional rehabilitation network to serve the Dallas-Fort Worth metroplex. This joint venture is subject to governmental approvals and it is anticipated that the joint venture will be approved and finalized within the normal process for governmental review.

6 Aug 2010

Salamander research findings bring scientists closer to future regenerative therapies

Tissue regeneration in salamanders and newts seems like it should be the stuff of science fiction. But it happens routinely. Why can't we mammals just re-grow a limb or churn out a few new heart muscle cells as needed? New research suggests there might be a very good reason: Restricting our cells' ability to pop in and out of the cell cycle at will - a prerequisite for the cell division necessary to make new tissue - reduces the chances that they'll run amok and form potentially deadly cancers.

6 Aug 2010

Therapy News and Research

Dr. Afar opens new dentistry office in North Hollywood, offers special promotion for new patients

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

SIRIUS XM Radio to broadcast call-in show for autism spectrum disorders

Asynchronous telepsychiatry provides primary-care physicians greater access to psychiatric consultation

Response Genetics total revenue for second-quarter 2010 increases 197% to $5.6 million

Scientists develop hand prosthesis that eases phantom pain

TrueBeam technology reduces cancer radiation treatment time

UCSF researchers discover new technology purifying special types of stem cells

Drugs that reduce activity of ABDH6 enzyme can prevent brain damage: Study

FDA declines to grant Levulan PDT Orphan Designation: DUSA Pharmaceuticals

Surgery offers high survival rate for prostate cancer patients: Study

OncoGenex reports net income in second-quarter 2010 against loss last year

BCF publishes two new patient publications

S-ICD subcutaneous implantable defibrillator restores normal heartbeat in high risk cardiac arrest

AVANIR Pharmaceuticals reports net loss of $5.7M for third-quarter fiscal 2010

Recent releases in Global Health

JumpStart Ventures announces investment commitment of $250,000 in ChanRx

ViroPharma announces data on safety, efficacy of Cinryze to treat acute angioedema attacks

Select Medical teams up with Baylor, joint venture to provide quality health care

Salamander research findings bring scientists closer to future regenerative therapies

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News